Who
Otis W. Brawley
Director
Company insider
Files Form 4 as: Director, Lyell Immunopharma; Director, Incyte; Director, Agilent Technologies; Director, PDS Biotechnology; Director, Theragenics.
In numbers
- Trades disclosed
- 46
- Buys
- 1
- Sells
- 0
- Bought
- $20K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 9 May 2006
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,250 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,250 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $241K2,158 at $111.75 | filing |
| 19 Mar 2026filed 23 Mar 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $99K888 at $111.75 | filing |
| 19 Mar 2026filed 23 Mar 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $241K2,158 at $111.75 | filing |
| 19 Mar 2026filed 23 Mar 2026 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $99K888 at $111.75 | filing |
| 12 Jan 2026filed 3 Mar 2026 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,876 at $0.00 | filing |
| 12 Jan 2026filed 3 Mar 2026 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,876 at $0.00 | filing |
| 11 Jun 2025filed 11 Jun 2025 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,700 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —9,216 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —2,518 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Bought | $20K35,640 at $0.56 | filing |
| 14 Mar 2025filed 18 Mar 2025 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $220K1,819 at $121.18 | filing |
| 14 Mar 2025filed 18 Mar 2025 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $98K812 at $121.18 | filing |
| 24 Jun 2024filed 25 Jun 2024 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
News
Lyell Immunopharma (NASDAQ:LYEL) versus Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Critical ComparisonLYEL · themarketsdaily.com · 20 Oct 2026Reviewing Neuphoria Therapeutics (NASDAQ:NEUP) & Lyell Immunopharma (NASDAQ:LYEL)LYEL · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Otis W. Brawley; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.